June 27, 2016 05:54 AM EDTUpdated September 18, 11:49 PM
Bioregnum
Opinion

The Zer­houni rule: “Every com­pa­ny that ac­quires a plat­form com­pa­ny kills it.”

Why Medi­va­tion makes the per­fect biotech takeover tar­get for Sanofi

Last Jan­u­ary at the J.P. Mor­gan con­fab, I had a chance to sit …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

RFK blog: Kennedy sur­vives Sen­ate grilling, with no bomb­shells to de­rail HHS con­fir­ma­tion

Trump ad­min­is­tra­tion makes first com­ments on how it will run IRA drug ne­go­ti­a­tions

8VC, a tech and life sci­ences VC firm be­hind Al­tos Labs, eyes $1B fund

Ex­clu­sive: Fer­til­i­ty start­up to be­gin Phase 3 study of stem cell ther­a­py for IVF

Ahead of earn­ings, Lil­ly culls mid-stage drug for heart fail­ure and chron­ic kid­ney dis­ease

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times